Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Medpace Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Medpace Holdings's regulatory disclosures and financial reporting.
Medpace Holdings, Inc. director Femida H. Gwadry-Sridhar received a grant of stock options covering 1,110 shares of common stock. The options have an exercise price of $415.27 per share and expire on May 15, 2033.
According to the terms, the option vests on the earlier of the day immediately preceding the first annual meeting of shareholders following the grant date, or the first anniversary of the grant date, subject to her continued service on the board of directors through the vesting date. Following this grant, she holds options for 1,110 shares directly.
DAVENPORT FRED B JR reported acquisition or exercise transactions in this Form 4 filing.
Medpace Holdings, Inc. director Fred B. Davenport Jr. received a grant of 1,110 stock options to buy common stock at $415.2700 per share, expiring on May 15, 2033. The options vest on the earlier of the day immediately preceding the first annual meeting following the grant date or the first anniversary of the grant, subject to his continued board service. Following this grant, he holds 3,498 shares directly and 2,000 shares indirectly through a trust.
Medpace Holdings, Inc. director Brian T. Carley reported an equity compensation award and updated holdings. He received a grant of stock options covering 1,110 shares of common stock with an exercise price of $415.27 per share, expiring on May 15, 2033.
The option vests on the earlier of the day immediately before the first Medpace annual meeting after the grant date or the first anniversary of the grant, subject to his continued service on the board. Following the reported transactions, Carley directly holds 32,789 shares of Medpace common stock and 1,110 stock options.
Troendle August J. reported acquisition or exercise transactions in this Form 4 filing.
Medpace Holdings, Inc. CEO August J. Troendle reported new equity awards and updated his holdings. He received 10,000 restricted stock units and 20,000 employee stock options, each tied to Medpace common stock. Both awards vest in full on the second anniversary of the grant date, subject to his continued employment.
Following these updates, Troendle holds 646,184 common shares directly and 4,733,019 common shares indirectly through Medpace Investors, LLC, where he has sole voting and investment control but disclaims beneficial ownership beyond his pecuniary interest.
Medpace Holdings, Inc. General Counsel & Corporate Secretary Stephen P. Ewald exercised employee stock options to acquire 3,500 shares of common stock at $138.87 per share. After this exercise, he directly holds 20,343 shares of common stock.
He also received equity compensation awards on the same date: 5,000 restricted stock units, each representing one share of Medpace common stock, and 10,000 employee stock options with a $410.54 exercise price expiring on April 24, 2033. The options that were exercised had vested in full on February 15, 2026, while the new RSUs and options vest in full on the fifth anniversary of the grant date, subject to his continued employment.
Medpace Holdings, Inc. disclosed that Executive Vice President of Operations Susan E. Burwig received new equity awards. She was granted 5,000 restricted stock units, each representing a contingent right to receive one share of MEDP common stock, and 10,000 employee stock options with an exercise price of $410.54 per share, expiring on April 24, 2033. Both the options and the restricted stock units vest in full on the second anniversary of the grant date, subject to her continued employment with Medpace or one of its subsidiaries. Following these transactions, she directly holds 70,484 shares of Medpace common stock, along with the newly granted awards.
Medpace Holdings, Inc. reported that CFO & Treasurer Kevin M. Brady exercised employee stock options for 7,000 shares of common stock at an exercise price of $138.87 per share, increasing his directly held common shares to 12,830.
On the same date, he received a grant of 5,000 restricted stock units, each representing a contingent right to one share of MEDP common stock, and a separate grant of 10,000 employee stock options with a $410.54 exercise price. The filing notes that the fully vested option exercised on April 24, 2026 had vested on February 15, 2026, while the new RSUs and options vest in full on the fifth anniversary of the grant date, subject to continued employment.
Medpace Holdings, Inc. reported strong first quarter 2026 results with revenue of $706.6 million, up 26.5% from $558.6 million a year earlier. GAAP net income was $123.9 million, or $4.28 per diluted share, compared with $114.6 million, or $3.67 per diluted share, as net income margin moved from 20.5% to 17.5%.
EBITDA increased 25.9% to $149.4 million with a 21.1% margin, while backlog rose 2.9% to $2,929.2 million and net new business awards were $618.4 million, yielding a 0.88x net book-to-bill ratio. Cash and cash equivalents reached $652.7 million. For full year 2026, Medpace forecasts revenue of $2.755–$2.855 billion, GAAP net income of $487.0–$511.0 million, EBITDA of $605.0–$635.0 million, and diluted EPS of $16.68–$17.50. The company also announced that President Jesse Geiger will retire effective May 31, 2026, with CEO August Troendle reassuming the President role until a successor is appointed.
Medpace Holdings director Cornelius P. McCarthy III exercised restricted stock units that converted into 29 shares of common stock on March 31, 2026. The award was part of a 113-unit grant from November 28, 2025 that vests in four approximately equal installments through December 31, 2026. Following this vesting event, he directly owns 10,324 shares of common stock and 84 restricted stock units, each representing a contingent right to receive one share of Medpace common stock.